Sotalol : interactions médicamenteuses

Class Ia antiarrhythmic drugs, such as disopyramide, quinidine, and procainamide, and other Class III drugs (for example, amiodarone) are not recommended as concomitant therapy, because of their potential for additive QTc prolongation [see Warnings and Precautions ( 5.1 )]. (notice Sotalol, Interactions médicamenteuses)

The use of SAPHRIS should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). (notice Asénapine, Mises en garde et précautions)

Drug Class Drugs within class that are contraindicated with REYATAZ Alpha 1-adrenoreceptor antagonist Alfuzosin Anticonvulsants Carbamazepine, phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with… (notice Atazanavir, Contre-indications)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (notice Azithromycine, Mises en garde et précautions)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (notice Ciprofloxacine, Mises en garde et précautions)

QT Prolongation : Avoid clarithromycin tablets in patients with known QT prolongation or receiving drugs known to prolong the QT interval, ventricular arrhythmia ( torsades de pointes ), hypokalemia/hypomagnesemia, significant bradycardia, or taking Class IA or III antiarrhythmics ( 5.2 ) (notice Clarithromycine, Mises en garde et précautions)

Class Ia antiarrhythmic drugs, such as disopyramide, quinidine, and procainamide, and other Class III drugs (for example, amiodarone) are not recommended as concomitant therapy, because of their potential for additive QTc prolongation [see Warnings and Precautions ( 5.1 )]. (notice Sotalol, Interactions médicamenteuses)

Class Ia antiarrhythmic drugs, such as disopyramide, quinidine, and procainamide, and other Class III drugs (for example, amiodarone) are not recommended as concomitant therapy, because of their potential for additive QTc prolongation [see Warnings and Precautions ( 5.1 )]. (notice Sotalol, Interactions médicamenteuses)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (notice Dofétilide, Mises en garde)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (notice Emtricitabine, rilpivirine et ténofovir, Mises en garde et précautions)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (notice Flécaïnide, Mise en garde encadrée)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (notice Fluconazole, Contre-indications)

Fosamprenavir calcium is contraindicated when coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine… (notice Fosamprénavir, Contre-indications)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (notice Foscarnet, Interactions médicamenteuses)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (notice Fosfomycine, Interactions médicamenteuses)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (notice Ilopéridone, Interactions médicamenteuses)

Antiarrhythmics Disopyramide Dofetilide Dronedarone Quinidine Contraindicated during and 2 weeks after TOLSURA treatment. (notice Itraconazole, Interactions médicamenteuses)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (notice Ivabradine, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (notice Lévofloxacine, Mises en garde et précautions)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (notice Sotalol, Mises en garde et précautions)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (notice Sotalol, Mises en garde et précautions)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (notice Sotalol, Mises en garde et précautions)

Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (notice Lopinavir et ritonavir, Contre-indications)

In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (notice Métirosine, Mises en garde)

Considering the known proarrhythmic properties of mexiletine and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of mexiletine as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmia. (notice Mexilétine, Mise en garde encadrée)

Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (notice Minoxidil, Mise en garde encadrée)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (notice Mirtazapine, Interactions médicamenteuses)

Therefore, moxifloxacin should be avoided with Class IA and Class III antiarrhythmics [see Warnings and Precautions ( 5.6 ), Nonclinical Toxicology ( 13.2 ), and Patient Counseling Information ( 17 )]. (notice Moxifloxacine, Interactions médicamenteuses)

Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (notice Nébivolol, Interactions médicamenteuses)

…concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7.3) ] : • Alpha 1-adrenoreceptor antagonist: alfuzosin • Antianginal: ranolazine • Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine • Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 2 , Drug Interactions… (notice Nirmatrelvir et ritonavir, Contre-indications)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (notice Oxaliplatine, Interactions médicamenteuses)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

Drugs that Prolong the QT Interval : Avoid concomitant use. (notice Phénobarbital, Interactions médicamenteuses)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (notice Pimozide, Contre-indications)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (notice Pitolisant, Mises en garde et précautions)

Class Ia (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) anti-arrhythmic drugs have been associated with cases of Torsades de Pointes in patients with bradycardia. (notice Ponésimod, Interactions médicamenteuses)

Class Ia antiarrhythmic drugs, such as disopyramide, quinidine, and procainamide, and other Class III drugs (for example, amiodarone) are not recommended as concomitant therapy, because of their potential for additive QTc prolongation [see Warnings and Precautions ( 5.1 )]. (notice Sotalol, Interactions médicamenteuses)

• The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk in patients with structural heart disease. (notice Propafénone, Mise en garde encadrée)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (notice Sotalol, Mises en garde et précautions)

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (notice Protamine, Mise en garde encadrée)

Class Ia antiarrhythmic drugs, such as disopyramide, quinidine, and procainamide, and other Class III drugs (for example, amiodarone) are not recommended as concomitant therapy, because of their potential for additive QTc prolongation [see Warnings and Precautions ( 5.1 )]. (notice Sotalol, Interactions médicamenteuses)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (notice Répaglinide, Interactions médicamenteuses)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (notice Ritonavir, Mise en garde encadrée)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (notice Rivastigmine, Interactions médicamenteuses)

Avoid the concomitant use of drugs known to prolong the QTc interval. (notice Sertraline, Interactions médicamenteuses)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (notice Sotalol, Mises en garde et précautions)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (notice Tétrabénazine, Interactions médicamenteuses)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (notice Sotalol, Mises en garde et précautions)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (notice Thioridazine, Contre-indications)

…Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (notice Tranylcypromine, Interactions médicamenteuses)

QT Prolongation : Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil hydrochloride tablets. (notice Vardénafil, Mises en garde et précautions)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (notice Vepdégestrant, Mises en garde et précautions)

Therefore, ziprasidone should not be given with: • dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. (notice Ziprasidone, Contre-indications)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Intervention: During concomitant use of mefenamic acid and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Acide méfénamique, Interactions médicamenteuses)

Antiarrhythmic and other QT Prolonging Drugs Withdraw other Class I or Class III antiarrhythmic agents prior to dosing with sotalol. (notice Sotalol, Interactions médicamenteuses)

Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (notice Sotalol, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (notice Sotalol, Mises en garde et précautions)

Beta Blockers The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. (notice Aspirine et dipyridamole, Interactions médicamenteuses)

Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (notice Aténolol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. (notice Bétaxolol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Table 4 Drug Interactions with BIXLENVO Concomitant Drug Class: Drug Name Effect on Concentration ↑ = Increase, ↓ = Decrease Clinical Comment Antiarrhythmics: digoxin dofetilide ↑ digoxin ↑ dofetilide Use digoxin with caution and monitor digoxin therapeutic concentration. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (notice Bupivacaïne, Mises en garde et précautions)

Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (notice Sotalol, Mises en garde et précautions)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (notice Buprénorphine, Mises en garde et précautions)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (notice Buprénorphine et naloxone, Mises en garde et précautions)

Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (notice Bupropion, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (notice Carvédilol, Interactions médicamenteuses)

Intervention: • During concomitant use of VYSCOXA and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Célécoxib, Interactions médicamenteuses)

DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (notice Céviméline, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (notice Cinacalcet, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Clonidine Concomitant use with sotalol increases the risk of bradycardia. (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

…initial dosing and titration of quetiapine. e.g. perphenazine, risperidone, thioridazine ↑ antipsychotics A decrease in the dose of antipsychotics that are metabolized by CYP3A or CYP2D6 may be needed when co-administered with PREZISTA/ritonavir. β-Blockers : e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring of patients is recommended. (notice Darunavir, Interactions médicamenteuses)

Initiation of quetiapine in patients taking PREZCOBIX or PREZCOBIX PED : Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine. β-Blockers: e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring is recommended for co-administration with beta-blockers that are metabolized by CYP2D6. (notice Darunavir et cobicistat, Interactions médicamenteuses)

QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Desflurane, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Intervention: During concomitant use of ZIPSOR and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Diclofénac, Interactions médicamenteuses)

• During concomitant use of diclofenac sodium/misoprostol and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Diclofénac et misoprostol, Interactions médicamenteuses)

Other Drugs with Anticholinergic Activity The following agents may increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine),… (notice Dicyclovérine, Interactions médicamenteuses)

Antiarrhythmic and other QT Prolonging Drugs Withdraw other Class I or Class III antiarrhythmic agents prior to dosing with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (notice Dihydroergotamine, Interactions médicamenteuses)

Antiarrhythmic and other QT Prolonging Drugs Withdraw other Class I or Class III antiarrhythmic agents prior to dosing with sotalol. (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (notice Éfavirenz, Interactions médicamenteuses)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (notice Éfavirenz, lamivudine et ténofovir, Interactions médicamenteuses)

Antiarrhythmics: e.g., amiodarone bepridil digoxin Indicates that a drug-drug interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine ↑ antiarrhythmics ↑ digoxin Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when coadministered with GENVOYA. (notice Elvitégravir, cobicistat, emtricitabine et ténofovir, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (notice Éribuline, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Antiarrhythmic and other QT Prolonging Drugs Withdraw other Class I or Class III antiarrhythmic agents prior to dosing with sotalol. (notice Sotalol, Interactions médicamenteuses)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (notice Étravirine, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

…as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, including baseline prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte… (notice Fentanyl, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Intervention: During concomitant use of flurbiprofen and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Flurbiprofène, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (notice Fluvoxamine, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (notice Glucagon, Interactions médicamenteuses)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (notice Glycopyrronium, Interactions médicamenteuses)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (notice Goséréline, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (notice Hydrocodone, Mises en garde et précautions)

During concomitant use of hydrocodone bitartrate and ibuprofen tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Hydrocodone et ibuprofène, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Intervention: During concomitant use of CALDOLOR and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Ibuprofène, Interactions médicamenteuses)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Ibuprofène et famotidine, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Intervention: During concomitant use of INDOCIN and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Indométacine, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Isoflurane, Mises en garde et précautions)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker. (notice Isradipine, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (notice Lacosamide, Mises en garde et précautions)

Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (notice Lanréotide, Interactions médicamenteuses)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (notice Lédipasvir et sofosbuvir, Mises en garde et précautions)

Clinical Comment Antiarrhythmics: digoxin ↑ digoxin Use with caution and monitor digoxin therapeutic concentration. (notice Lénacapavir, Interactions médicamenteuses)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (notice Leuproréline, Mises en garde et précautions)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Antiarrhythmic and other QT Prolonging Drugs Withdraw other Class I or Class III antiarrhythmic agents prior to dosing with sotalol. (notice Sotalol, Interactions médicamenteuses)

Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (notice Sotalol, Mises en garde et précautions)

Antiarrhythmic and other QT Prolonging Drugs Withdraw other Class I or Class III antiarrhythmic agents prior to dosing with sotalol. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (notice Lofexidine, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (notice Méfloquine, Interactions médicamenteuses)

Intervention: During concomitant use of QAMZOVA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Méloxicam, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (notice Méthylergométrine, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (notice Métronidazole, Interactions médicamenteuses)

There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (notice Mifépristone, Mises en garde et précautions)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (notice Motixafortide, Mises en garde et précautions)

Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (notice Naltrexone et bupropion, Interactions médicamenteuses)

Intervention: During concomitant use of Naproxen Suspension and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Naproxène, Interactions médicamenteuses)

Intervention : • During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Naproxène et ésoméprazole, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (notice Névirapine, Interactions médicamenteuses)

However, titrate slowly when using CARDENE I.V. in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2) ]. (notice Nicardipine, Interactions médicamenteuses)

These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients using concomitant beta-blockers. (notice Nifédipine, Mises en garde)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (notice Nimodipine, Interactions médicamenteuses)

Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (notice Octréotide, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Intervention: During concomitant use of OXAPROZIN CAPSULES and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Oxaprozine, Interactions médicamenteuses)

Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. (notice Oxymétazoline, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Paracétamol et ibuprofène, Interactions médicamenteuses)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (notice Pasiréotide, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (notice Phénelzine, Mises en garde)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (notice Pilocarpine, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Piroxicam, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Hypotension may develop in patients given prazosin hydrochloride capsules who are also receiving a beta-blocker such as propranolol. (notice Prazosine, Mises en garde)

Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (notice Sotalol, Mises en garde et précautions)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (notice Primaquine, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (notice Pyridostigmine, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

…non-hormonal methods of birth control during rifampin therapy Estrogens Decrease exposure Progestins Anticonvulsants Phenytoin Administered with rifampin 450 mg daily Decrease exposure Antiarrhythmics Disopyramide Decrease exposure Mexiletine Decrease exposure Quinidine Decrease exposure Propafenone Decrease AUC by 50%-67% Tocainide Decrease exposure Antiestrogens… (notice Rifampicine, Interactions médicamenteuses)

Table 4: Drug Interactions with PRIFTIN: Dosage Adjustment May be Necessary Drug Class Examples of Drugs Within Class Antiarrhythmics Disopyramide, mexiletine, quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine… (notice Rifapentine, Interactions médicamenteuses)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (notice Rilpivirine, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (notice Rocuronium, Mises en garde et précautions)

Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (notice Ropivacaïne, Mises en garde et précautions)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (notice Sofosbuvir et velpatasvir, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (notice Sous-citrate de bismuth, métronidazole et tétracycline, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (notice Sumatriptan et naproxène, Interactions médicamenteuses)

Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Antihypertensives Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects. (notice Trinitrine, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (notice Triptoréline, Mises en garde et précautions)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Antiarrhythmic and other QT Prolonging Drugs Withdraw other Class I or Class III antiarrhythmic agents prior to dosing with sotalol. (notice Sotalol, Interactions médicamenteuses)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (notice Sotalol, Interactions médicamenteuses)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (notice Sotalol, Interactions médicamenteuses)

Zileuton increases propranolol levels and beta-blocker activity. (notice Zileuton, Interactions médicamenteuses)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (notice Amoxapine, Interactions médicamenteuses)

Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. (notice Bisoprolol, Interactions médicamenteuses)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (notice Carbamazépine, Interactions médicamenteuses)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (notice Clomipramine, Interactions médicamenteuses)

Effects on the absorption of other beta-blockers have not been determined. (notice Colestipol, Interactions médicamenteuses)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). (notice Désipramine, Interactions médicamenteuses)

Other Cardiovascular Agents Enalaprilat injection, USP has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. (notice Énalaprilate, Interactions médicamenteuses)

In controlled clinical trials, however, beta-blockers including metoprolol were concurrently administered with felodipine and were well tolerated. (notice Félodipine, Interactions médicamenteuses)

ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). (notice Fénoprofène, Interactions médicamenteuses)

…PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (notice Finastéride, Interactions médicamenteuses)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (notice Imipramine, Interactions médicamenteuses)

Cardiac Rhythm and Conduction Abnormalities In vitro testing showed that lamotrigine exhibits Class IB antiarrhythmic activity at therapeutically relevant concentrations [see Clinical Pharmacology ( 12.2 )] . (notice Lamotrigine, Mises en garde et précautions)

Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant. (notice Nisoldipine, Interactions médicamenteuses)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (notice Nortriptyline, Interactions médicamenteuses)

Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (notice Pentoxifylline, Interactions médicamenteuses)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (notice Perphénazine, Interactions médicamenteuses)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). (notice Protriptyline, Précautions)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (notice Telmisartan et amlodipine, Interactions médicamenteuses)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (notice Terbinafine, Interactions médicamenteuses)

Moderate or Weak CYP1A2 Inhibitors Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. (notice Tizanidine, Interactions médicamenteuses)

Angiotensin Receptor Blockers, Angiotensin Converting Enzyme Inhibitors and Potassium Sparing Diuretics Although specific interaction studies were not performed, in clinical studies, tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. (notice Tolvaptan, Interactions médicamenteuses)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (notice Trimipramine, Interactions médicamenteuses)